Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
Annals of Rheumatic Diseases Mar 09, 2018
Gabay C, et al. - Experts assessed whether interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in adult-onset Still’s disease (AOSD). As per findings, tadekinig alfa appeared to have a favourable safety profile and was related to early signs of effectiveness in patients with AOSD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
